DexCom, Inc.
No trades
Trade ideas
LONG DXCM High Alpha Momentum RSI Breakout PlayDXCM flirting with new highs while RSI looks pretty constructive. This looks like it might run a bit so while it might be a nice quick momentum play there is probably a lot of long term appeal here. This also applies to AYX which I just posted.
DXCM flagSymbol DXCM
setup flag
Upcoming Earnings Jan 29, 2019 (EST) Feb 21, 2019 (EST)
Horizontal S&R: yes 138
Channel S&R: no
MA S&R: yes bounced off of 20ma
>200ma: yes
Volume confirmation: ok
Candle Confirmation: yes morning star
Stoch Divergence: no
Reg Trendline >85: no
Short Float: 7%
Entry 152
Stop 137
Price Target 182
Risk / Reward: 1:2
Zacks Rank: 2-Buy 2 Style Scores: D Value | A Growth | F Momentum | C VGM Industry Rank: Top 27%(67 out of 255) Industry: Medical - Instruments
Any feedback is welcomed.
DexCom's CGM is the FUTURE.Clearly, that Dec 24 route was the clear buying opportunity, You would've been +40% by now.
Is it too late? I'd say NO.
If you have the ability to invest on this, and of course, have an awareness on all the geopolitical factors. I think this is a win.
If you want to swing, it's also up to you.
Here's the thing
1) Let's be clear, DexCom is the leader on CGM (continuous glucose monitoring). BTW, best presentation on JPM Conference.
2) G6 is being sold to partners like tandem, lily, insulet, and novo, basically eating on their lunch.
FY18 revenue estimate is from $830m to $850m. ($715m the year before). CEO Kevin Sayer expects revenue to exceed $331m
3) Regarding their collaboration with Verily(GOOG), they expect a product with a lower cost;
smaller, longer life, &disposable which benefits those who aren't using CGM yet.
3) The future - There are a lot of people that need to be (and will be) screened, not to mention pre-diabetics.
My take: There's so much room to improve the G6 tech. I'm thinking, insulin delivery system kind of like tandem's t:slim.
That way, they can serve type 2 diabetics.
I like Tandem and I think the collaboration is perfect and I think the Verily product will take the stock higher.
Also, a sensor that goes straight to the Apple Watch $AAPL so the patient doesn't have to carry a phone.
Strategy: Obtain approval to launch G6 globally; Focus on the rollout to Medicare population.
Price Target: Call me crazy but I think DXCM can trade up to Abiomed's level. $320-400. Why?
I think this is a monopoly in CGM, and they can execute globally.
Strong uptrend waiting for a short pullbackThis stock has been strong but is a little bit over extended on the weekly chart. Once it pulls back on the weekly it will be a strong buy.
DXCM
DEXCOM ShortWe can see that, dex com finished his waves and when we look at the rsi we can see the unconformity. Target is 91 dollars.
DXCM - fallen angel type long from $50.37 to $56.43DXCM was in our watch list from a while, and it seems its started to move now. If it can breaks its resistance around $50.37 it can go as high as $57 area
* Trade Criteria *
Date First Found- November 6, 2017
Pattern/Why- Fallen angel
Entry Target Criteria- Break of $50.37
Exit Target Criteria- $56.43
Stop Loss Criteria- $47.77
Please check back for Trade updates. (Note: Trade update is little delayed here.)
Dexcom Shares: Potential 8x Rise Next 3 YearsRecently shares of the Dexcom Inc., that are traded on the NASDAQ exchange, probably have made the bottom and started a new uptrend. Dexcom is a medical device company. The company is focused on development of continuous glucose monitoring systems. Let's look at the price movements of this stock (which is traded at $85.13 now) from the technical point of view. Here is the monthly chart.
Clear motive Elliott Wave structure
There is a pretty clear and obvious motive Elliott Wave structure here, started in 2009.
The top of the wave 1 occured in April 2011, followed by the mid-term downtrend presented by the wave 2 (a zigzag pattern), which was ended in November 2011. After that, the motive wave 3 took place till September 2015. And in the September 2015 - December 2016 period we can see the wave 4 that seems like a "running flat" correction pattern. And there is a high possibility of the new motive wave 5 beginning right now.
And everything fits into a correct trend channel.
Wave symmetry
Wave 1 had 1,147% growth and 29 months length.
Wave 3 had 1,417% growth and 46 months length.
The coming wave 5 should have the same or comparable percentage of growth and the same or comparable length. So there is a high possibility of at least 1,100% growth in the next 3 years, compared to the recent bottom at $57. The calculated price target is around $600 by 2020.
Trend channel
By the trend channel rules, we can see the similar price and time targets.
The price is likely to make the next top at the upper line of the trend channel, which shows us ~$680 somewhere in 2020.
Moreover, the trend channel can help us to recognize early if the forecast is incorrect: in the unlikely case the price fails to reach the target and falls below the lower line of the trend channel, then this wave structure will become invalid and we need to re-analyse it and get out of the market.
The year 2020. Again.
Dexcom is another asset that is gonna have long-term reversal in 2020. See my previous articles:
US Dollar Index Likely to Make Grand Top in 2020
The best time to invest in Dubai will be the year 2020
Dexcom will continue going longthe stock has cleared in one day a 3 months of downtrend. what a great move only from rumers.
I think we should let the stock pull back up to 83 and then look for an entrance when the potencial is up to 93.
very good for long although the market is going sideway or even will go a bit bearish
DXCM Dexcom symmetrical pennant/triangle flagsorry about the squiggly, lines - this is my first chart. Anyone agree with what I see? I've been in this one since the low 20s and this company has some killer products and devices in the pipeline as well as 3 pending FDA approvals that will increase the bottom line. I'm
Possible break of 20 month trendlineAfter a strong push to the T/L and slight pullback, buyers stepped in aggressively on Friday. There is not much resistance over 15.60. The first target is the 2011 highs near 17.
